Page 456«..1020..455456457458..470480..»

Gene Therapy Market Research Report 2022: Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy – Global Forecast to 2027 – Cumulative…

Posted: May 15, 2022 at 2:07 am

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market Research Report by Type (Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy), Vector Type, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Market size was estimated at USD 2,828.62 million in 2021, USD 3,463.59 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 22.62% to reach USD 9,617.32 million by 2027.

In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Cumulative Impact of COVID-19:

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.

It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.

Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report answers questions such as:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Limitations

1.7. Assumptions

1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective

2.2. Determine: Research Design

2.3. Prepare: Research Instrument

2.4. Collect: Data Source

2.5. Analyze: Data Interpretation

2.6. Formulate: Data Verification

2.7. Publish: Research Report

2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers

5.1.1.1. Significant way of treatment to eradicates the practice of surgery, drugs, or other procedures that lead to side effects on the health of individuals

5.1.1.2. Innovation in gene therapy for rare & cardiovascular diseases treatment coupled with the awareness regarding the ability of gene therapy

5.1.1.3. Application in the treatment of various diseases such as cancer, haemophilia, parkinson's disease, and HIV

5.1.1.4. Government support and ethical acceptance of gene therapy for cancer treatment

5.1.2. Restraints

5.1.2.1. High cost associated with the gene therapies

5.1.3. Opportunities

5.1.3.1. Upsurge in a number of gene therapy treatment centers in developed countries

5.1.3.2. Increasing adoption for gene therapy for the oncological disorder

5.1.3.3. Growing strategic alliances and ongoing research for orphan diseases

5.1.4. Challenges

5.1.4.1. Potential disorders associated with the immune response

5.2. Cumulative Impact of COVID-19

5.3. Cumulative Impact of 2022 Russia Ukraine Conflict

6. Gene Therapy Market, by Type

6.1. Introduction

6.2. Antigen Gene Therapy

6.3. Cancer Gene Therapy

6.4. Cytokine Gene Therapy

6.5. Suicide Gene Therapy

6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

7.1. Introduction

7.2. Non-viral Vectors

7.3. Viral Vectors

8. Gene Therapy Market, by Application

8.1. Introduction

8.2. Cardiovascular Diseases

8.3. Genetic Diseases

8.4. Infectious Diseases

8.5. Neurological Diseases

8.6. Oncological Disorders

For more information about this report visit https://www.researchandmarkets.com/r/mfwu95

Originally posted here:
Gene Therapy Market Research Report 2022: Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy - Global Forecast to 2027 - Cumulative...

Posted in Gene therapy | Comments Off on Gene Therapy Market Research Report 2022: Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy – Global Forecast to 2027 – Cumulative…

AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion – GlobeNewswire

Posted: May 15, 2022 at 2:07 am

Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of 2022

GAINESVILLE, Fla. andCAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation(Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, recently hosted a topping off ceremony for its state-of-the-art gene therapy manufacturing facility during the BioFlorida Celebration of Biotechnology, signaling the completion of the buildings exterior structure.

Leasing our own manufacturing facility is an essential part of our strategy to support the near term production of materials for upcoming clinical trials and eventually the potential production of commercial supply for any approved products, said President and CEO of AGTC, Sue Washer. We were thrilled to host this event as part of BioFloridas Celebration of Biotechnology and contribute to a growing biotech presence in the state. We look forward to the grand opening later this year and welcoming everyone to the facility.

The new manufacturing building is part of the Companys strategy to exert more control over its manufacturing needs and enable a more rapid filing of a Biologics Licensing Application and, if approved by the FDA, support the commercial launch of its XLRP candidate. The facility is also expected to support more rapid advancement of the Companys product pipeline, providing improved quality assurance and supply chain redundancy while reducing manufacturing risk.

The event, held on May 5, began with remarks from BioFloridas President & CEO, Nancy Bryan, Matt Cason, President of Concept Companies, the project developer, and Sue Washer, President and CEO of AGTC. The event was attended by many in the local biotech community as well as the vendors and sub-contractors supporting the project. To commemorate the event, key members of the project team signed the last beam to be put in place this week.

About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3). Its preclinical programs build on the companys industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical needs in optogenetics, otology and CNS disorders, and has entered strategic collaborations with companies including Bionic Sight, an innovator in the emerging field of optogenetics, and retinal coding and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. For more information, please visithttps://agtc.com/.

Forward-Looking StatementsThis release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs, including statements about the potential of the companys gene therapy platform, the strength of its XLRP clinical program, whether clinical trial results will support future regulatory filings, the expected timing for completion of the manufacturing facility and the potential for the new manufacturing facility to support AGTCs pipeline programs. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due toa number ofimportant factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; risks and uncertainties related to funding sources for our development programs; the direct and indirect impacts of the ongoing COVID-19 pandemic on the Companys business, results of operations, and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the companys most recent annual report on Form 10-K, as it may be supplemented by subsequent periodic reports filed with theSEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

PR Contact:

Kerry Sinclair

Spectrum Science Communications

ksinclair@spectrumscience.com

Corporate Contact:

Jonathan Lieber

Chief Financial Officer

Applied Genetic Technologies Corporation

T: (617) 843-5778

jlieber@agtc.com

Here is the original post:
AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building's Structural Completion - GlobeNewswire

Posted in Gene therapy | Comments Off on AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion – GlobeNewswire

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT) – PR Newswire

Posted: May 15, 2022 at 2:07 am

--ARU-1801 reducedvaso-occlusive events and days in the hospital for patients with severe sickle cell disease--

MILLBURN, N.J. and BASEL, Switzerland, May 12, 2022 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that data demonstrating the clinical benefit of the company's lead product candidate ARU-1801 for severe sickle cell disease (SCD) will be presented today in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th annual meeting.Punam Malik, M.D., Director of the Cincinnati Comprehensive Sickle Cell Center and Program Leader of the Hematology and Gene Therapy Program at the Cincinnati Children's Hospital Medical Center, will deliver the oral presentation this afternoon at 1:30 PM EDT.

"The data demonstrate that the ARU-1801 gene therapy may not only be able to reduce severe vaso-occlusive events (VOEs) but also reduce days in the hospital for SCD patients which could provide a clinically meaningful benefit for patients and help reduce health care costs," said Dr. Malik. "ARU-1801 is the only gene therapy in development that has been shown to achieve durable responses in patients with severe SCD using only reduced intensity conditioninga key differentiator from other investigational gene therapy and gene editing regimens."

Dr. Malik will be presenting data from the ongoing MOMENTUM Phase 1/2 clinical trial that is examining ARU-1801, an autologous lentiviral cell therapy with a modified, highly potent gamma globin payload, in individuals with severe SCD. ARU-1801 is designed to address the limitations of current curative allogeneic transplant options, such as low donor availability, the risk of graft-versus-host disease and toxicity from myeloablative chemotherapy. Unlike investigational gene therapies that require fully myeloablative conditioning, ARU-1801 is given with reduced intensity conditioning (RIC), which is a lower dose chemotherapy associated with less chemotherapy side effects including shorter time in the hospital and less short- and long-term toxicity than myeloablative approaches.

The data being presented demonstrates:

The ASGCT annual meeting is taking place in Washington, D.C. and virtually starting today, May 16, and will go through to May 19, 2022. For more information about the conference, please visit https://annualmeeting.asgct.org/.

About Aruvant SciencesAruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. The company has a talentedteamwith extensive experience in the development, manufacturing and commercialization of gene therapy products. Aruvant has an activeresearchprogram with a lead product candidate, ARU-1801, in development for individuals suffering fromSCD. ARU-1801, an investigational lentiviral gene therapy, is being studied in aPhase 1/2 clinical trial,the MOMENTUM study, as a one-time potentially curative treatment for SCD. Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy. The company's second product candidate, ARU-2801, is in development to cure hypophosphatasia, a devastating, ultra-orphan disorder that affects multiple organ systems and leads to high morbidity and mortality when not treated. Data from pre-clinical studies with ARU-2801 shows durable improvement in disease biomarkers and increased survival. For more information on the ongoing ARU-1801 clinical study, please visit https://sicklecellstudies.com/, and for more on the company, pleasevisitwww.aruvant.com. Follow Aruvant on Facebook, Twitter @AruvantSciences, Instagram @Aruvant_Sciencesor LinkedIn @AruvantSciences.

SOURCE Aruvant Sciences

Go here to read the rest:
Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT) - PR Newswire

Posted in Gene therapy | Comments Off on Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT) – PR Newswire

UAB Callahan Eye Hospital offering new gene therapy treatment for an inherited retinal disease – Alabama NewsCenter

Posted: May 15, 2022 at 2:07 am

TheUniversity of Alabama at Birmingham Callahan Eye Hospital has been named one of the newest sites for Spark Therapeutics Luxturna, the first gene therapy treatment approved by the Food and Drug Administration for a genetic disease.

It is a prescription gene therapy for patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can be confirmed only through genetic testing. Patients must have viable retinal cells as determined by the treating physicians.

Leber congenital amaurosis (LCA) is one retinal degenerative condition and a leading cause of genetic blindness in children. Patients with LCA start to lose their vision in the first five years of life, and it gets progressively worse as they age. Most patients are considered legally blind due to the profound vision loss it causes.

One subtype is caused by inherited mutations in both copies of the RPE65 gene. When patients have mutations in both copies of their RPE65 gene, the normal visual cycle cannot take place and retinal cells die over time.

Luxturna uses a non-disease-causing virus to deliver a normal copy of the RPE65 gene to retinal cells, enabling them to make proteins that have the potential to make the visual cycle work properly again.

Dr. Jason Crosson and Dr. Richard Feist Jr. of Retina Consultants of Alabama will treat patients with RPE65 LCA, also known as LCA 2, at UAB Callahan Eye Hospital.

We are excited to offer patients with this debilitating condition the opportunity to see more clearly in low-light environments for the first time in their lives, said Dr. Dawn DeCarlo, director of the UAB Center for Low Vision Rehabilitationin theMarnix E. Heersink School of Medicine. Patients in our area who were previously identified as good candidates for Luxturna have had to travel to other states to receive treatment. It is exciting that we will now not only be able to offer patients from Alabama treatment right here at UAB Callahan Eye Hospital, but we will also be a destination treatment center for patients throughout the Southeast.

UAB is now one of 14 treatment locations in the nation, and one of the few sites in the Southeast.

Our location, in Birmingham, is an asset because of our reputation as a top national eye center and the accessibility of our city for those living in the Southeast, said Brian Samuels, interim chair for the UAB Department of Ophthalmology and Visual Sciences. I am extremely proud of Drs. Paul Gamlin, Douglas Witherspoon, Dawn DeCarlo, Jason Crosson and Richard Feist Jr., who were instrumental in UABs becoming a designated treatment center.

We have already been notified there are patients from Alabama and the Southeast who are interested in receiving treatment here, Crosson said. We look forward to meeting our new patients soon and scheduling them for treatment.

This story originally appeared on theUAB News website.

Continue reading here:
UAB Callahan Eye Hospital offering new gene therapy treatment for an inherited retinal disease - Alabama NewsCenter

Posted in Gene therapy | Comments Off on UAB Callahan Eye Hospital offering new gene therapy treatment for an inherited retinal disease – Alabama NewsCenter

Particle Therapy Market to Surpass Value of US$ 1.2 Bn by 2031, Observes TMR Study – PR Newswire

Posted: May 15, 2022 at 2:07 am

ALBANY, N.Y., May 13, 2022 /PRNewswire/ --The value of the global particle therapy market stood at US$ 560.3 Mn in 2021. The global market is likely to rise at a CAGR of 8.6% during the forecast period, from 2022 to 2031. The global particle therapy market is anticipated to cross the value of US$ 1.2 Bn by 2031. Minimal risk of treatment-induced illnesses,risein cancer incidences, and increase in number of particle therapy centers throughout the world are projected to be the growth factors for the particle therapy market. Proton therapy's main objective is to enhance radiation therapy by employing proton beams in the treatmentof targeted tumors and radiosurgery.

A surge in the number of trials has demonstrated the positive effects of particle therapy in certain clinical settings, and breakthroughs in image guidance,beam delivery,as well astreatment planning are predicted to facilitatepositive particle therapy market projections during the forecast period. In addition, favorable clinical findings have resulted in a growth in the number of treatment centers globally, with some in the construction orplanningstages.

Companies in the global particle therapy marketare turning difficult cooperation initiatives and ideas into solutions fosteringsocial innovation to improve patient outcomes. Top research and care institutions are collaborating to promote radiotherapy advancements. Technological advancements in cyclotron devices are driving the market.

Request Brochure of Particle Therapy Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56133

Key Findings of Market Report

Request for Analysis of COVID-19 Impact on Particle Therapy Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56133

Global Particle Therapy Market: Growth Drivers

Get Exclusive PDF Sample Copy of Particle Therapy Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=56133

Global Particle Therapy Market: Key Players

Some of the key market players are

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=56133

Global Particle Therapy Market: Segmentation

Therapy

Service

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated withLatest Healthcare Industry Research Reportsby Transparency Market Research:

Cancer Gene Therapy Market: Increase in prevalence of cancer, rise in government funding and initiatives, growth in pipeline of cancer gene therapy products, and collaborations to develop and launch gene-therapy products are some factors driving the market.

Gene Therapy Market: Increase in competition among the leading biopharmaceutical companies to approve and commercialize gene therapy products in different areas of unmet medical needs to gain the first mover advantage is expected to boost the growth of the gene therapy market during the forecast period.

CAR T-cell Therapy Market: The CAR T-cell therapy is emerging as a breakthrough innovation in cancer treatment. Clinical trials conducted globally are showing promising results in end stage patients and especially, for patients suffering from Acute Lymphocytic Leukemia. Such findings are translating into revenue opportunities for companies in the CAR T-cell therapy market.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey

Transparency Market ResearchState Tower,90 State Street, Suite 700,Albany NY 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: [emailprotected]Follow Us: Twitter | LinkedInBlog: https://tmrblog.comBrowse PR https://www.transparencymarketresearch.com/pressrelease/particle-therapy-market.htm

SOURCE Transparency Market Research

Original post:
Particle Therapy Market to Surpass Value of US$ 1.2 Bn by 2031, Observes TMR Study - PR Newswire

Posted in Gene therapy | Comments Off on Particle Therapy Market to Surpass Value of US$ 1.2 Bn by 2031, Observes TMR Study – PR Newswire

Blood Emergency declared in Rhode Island and Connecticut – What’sUpNewp

Posted: May 15, 2022 at 2:06 am

Rhode Island Blood Center (RIBC) and Connecticut Blood Center (CTBC) announced today a blood emergency, as school breaks and increased travel have caused an alarming drop in donations.

According to a press release, the blood supply currently stands at a 2-to-3-day level; platelets along with types O and B- are at just a 1-to-2-day supply. This is well below the ideal inventory of 5-7 days.

Hospitals and patients rely upon a steady flow of volunteer donors to receive life-saving blood donations. According to the latest figures put out by Americas Blood Centers, only 3 percent of the U.S. population donates blood.

This time of year can always be difficult for the blood supply, with school breaks and increased travel making blood donations less of a priority, saidBeau Tompkins, Senior Executive Director of the RI & CT Blood Centers.We highly encourage all who are able to please donate today to help us meet this critical need in our community.

According to the press release, it only takes one hour to donate, and a single donation can save multiple lives. Roughly one in seven hospital admissions requires a blood transfusion. Those in need include cancer patients, accident, burn, or trauma victims, transplant recipients, surgery patients, chronically transfused patients suffering from sickle cell disease or thalassemia, and many more.

To make an appointmentcall 800.283.8385 or visitribc.orgorctblood.org.

RHODE ISLAND BLOOD CENTER(RIBC) was founded in 1979 as a nonprofit community blood center. For over 35 years, RIBC has been the primary supplier of blood and blood products to patients being cared for in hospitals throughout Rhode Island and in neighboring states. Our mission is to help save lives by ensuring a safe and plentiful blood supply to the patients and hospitals we serve. RIBC is also part of the National Marrow Donor Program and collects stem cells for transplant at its Providence location. RIBC provides therapeutic treatments for patients in local hospitals. Our state-of-the-art laboratory performs donor testing for over 400,000 donations per year. RIBC is also involved in various local and national research programs to improve all aspects of the blood supply. RIBC is a division of New York Blood Center, Inc. (a family of operating Divisions known as New York Blood Center Enterprises). For more information, visitribc.org.

CONNECTICUT BLOOD CENTER(CTBC) supplies blood and blood products to patients being cared for in over a dozen Connecticut hospitals. CTBC operates a hospital services blood storage depot from our Connecticut center so we can quickly and reliably get urgent or unexpected orders to local hospitals. CTBC is operated by the Rhode Island Blood Center, a part of theNew York Blood Center Enterprisesfamily with more than five decades of experience saving lives by ensuring a safe and plentiful blood supply to the patients and hospitals we serve. CTBC is also part of the National Marrow Donor Program, registering individuals throughout New England to become lifesaving stem cell donors for patients who need a transplant to survive.

The rest is here:
Blood Emergency declared in Rhode Island and Connecticut - What'sUpNewp

Posted in Rhode Island Stem Cells | Comments Off on Blood Emergency declared in Rhode Island and Connecticut – What’sUpNewp

Paul Choi and Leslie Tolbert to lead Board of Overseers – Harvard Gazette

Posted: May 15, 2022 at 2:06 am

Paul Choi 86, J.D. 89, a longtime Harvard alumni leader and a lawyer with expertise on governance, has been elected president of Harvard Universitys Board of Overseers for the 202223 academic year. Leslie Tolbert 73, Ph.D. 78, a neuroscientist and former senior vice president for research at the University of Arizona, will serve as vice chair of the boards executive committee. Both elected as Overseers in 2017, Choi and Tolbert will serve in the boards top leadership roles for the final year of their six-year terms.

Paul Choi and Leslie Tolbert have both served Harvard with uncommon devotion and distinction, especially during their past five years as Overseers, said President Larry Bacow. Paul has deep experience with the governance of complex organizations, including Harvard, and a long record of leadership in alumni affairs. Leslie is a widely admired scientist, educator, and academic leader who has in recent years played a particularly valuable role in our visiting committee process. I look forward to working even more closely with them next year, as the Overseers continue to help guide the University through times of challenge and change.

Choi and Tolbert succeed Helena Buonanno Foulkes 86, M.B.A. 92, a past executive in the consumer health care and retail sectors who is currently running for governor of Rhode Island, and P. Lindsay Chase-Lansdale 74, a developmental psychologist and former vice provost for academics at Northwestern University.

Paul Choi is a partner at the international law firm Sidley Austin LLP, where he is a member of his firms executive committee and global co-head of its mergers and acquisitions practice. He has a long record of advising clients on a broad range of governance matters. His professional honors include longstanding recognition in the Chambers publication The Worlds Leading Lawyers for Business, and he was recently recognized as lawyer of the year for his work in corporate governance law in Chicago in the 2021 edition of The Best Lawyers in America.As a member of Harvards Board of Overseers, Choi chairs the boards institutional policy committee and the boards working group on elections. He also serves on the Overseers executive committee and its subcommittee on governance, the governing boards joint committee on alumni affairs and development, and the standing committee on social sciences, of which he is the former vice chair. He also is serving or has served on the visiting committees for Harvard College, the Economics Department, Harvard Law School, and the Harvard T.H. Chan School of Public Health.

Its a tremendous honor and privilege to be elected as president of the Board of Overseers and to have the opportunity to serve the University and my fellow board members in this new role, said Choi. I look forward to working with President Larry Bacow, the Harvard leadership, and my Overseer colleagues in advancing the academic mission of our extraordinary institution and navigating the many challenges and opportunities which lie ahead. Choi added that hes grateful to have Leslie Tolbert, a distinguished scientist and wonderful colleague, as a partner in leading the board.

Long one of Harvards most engaged alumni leaders, Choi served as president of the Harvard Alumni Association in 2015-16 and as a member of the HAA executive committee from 2011 to 2020. He served as an elected director of the HAA board from 2009 to 2012. A past president of the Harvard Club of Chicago and a reunion leader for his College and Law School classes, Choi also has been an alumni interviewer for three decades. He is a member of the deans leadership council at Harvard Law School, as well as the advisory board for the HLS Program on Corporate Governance.

Choi graduated from Harvard College, magna cum laude, in 1986 and went on to earn a J.D., magna cum laude, from Harvard Law School in 1989, where he was an editor of the Harvard Law Review and was awarded the Sears Prize. After graduation, he served as a law clerk on the United States Court of Appeals for the D.C. Circuit.

A strong advocate for university-based research and for interdisciplinary studies, Leslie Tolbert is Regents Professor Emerita in Neuroscience at the University of Arizona. Her career at the university has included such leadership roles as senior vice president for research; vice president for research, graduate studies, and economic development; interim dean of the graduate college; and chair of the campus-wide committee on neuroscience. Her own neuroscience research has focused on the impact of sensory input on the development of brain circuitry, the interactions of neurons and glial cells, and the development and plasticity of the olfactory system.

As a Harvard Overseer, Tolbert serves on the executive committee, chairs its subcommittee on visitation, and also chairs the boards committee on natural and applied sciences. In addition, she sits on the committee on Schools, the College, and continuing education, the joint committee on alumni affairs and development, and the joint committee on appointments. Besides her overall leadership on visitation matters, she chairs the visiting committee for the Harvard Library and has served on visiting committees for Harvard Medical School and School of Dental Medicine and for several academic departments: Human and Evolutionary Biology, Psychology, and Stem Cell and Regenerative Biology.

Im honored by the opportunity to serve as vice chair of the Board of Overseers executive committee, said Tolbert. I joined the board to give back to the institution that plays such an important national and international role and shaped so much of my own personal and professional lives. Now, I look forward to working even more closely with Paul Choi and my other Overseer colleagues to help President Bacow, Provost Alan Garber, and other Harvard leaders advance and renew Harvards tradition of excellence and its leadership across so many domains.

Tolbert graduated cum laude from Harvard College in 1973. She earned her Ph.D. in anatomy from Harvard in 1978, through the Division of Medical Sciences, and continued as a postdoctoral fellow at Harvard Medical School. After five years on the faculty of the Georgetown University School of Medicine, she moved to the University of Arizona in 1987, became a tenured full professor in 1995, and was named Regents Professor in 2002.

An expert on early brain development and brain plasticity, she was named a fellow of the American Association for the Advancement of Science (AAAS) for her outstanding contribution to knowledge of the intercellular interactions between developing and mature neurons and glial cells and service to academic research and professional societies. She has served on numerous committees, councils, and advisory boards for government agencies, universities, research institutions, and professional associations. An early member of the Society for Neuroscience and past president of its Tucson chapter, she is also past president of the Association of Neuroscience Departments and Programs and of the Association for Chemoreception Sciences.

The Board of Overseers is one of Harvards two governing boards, along with the President and Fellows, also known as the Corporation. Formally established in 1642, the board plays an integral role in the governance of the University. As a central part of its work, the board directs the visitation process, the primary means for periodic external assessment of Harvards Schools and Departments. Through its array of standing committees, and the roughly 50 visiting committees that report to them, the board probes the quality of Harvards programs and assures that the University remains true to its charter as a place of learning. More generally, drawing on its members diverse experience and expertise, the board provides counsel to the Universitys leadership on priorities, plans, and strategic initiatives. The board also has the power of consent to certain actions such as the election of Corporation members, including the president.

See the article here:
Paul Choi and Leslie Tolbert to lead Board of Overseers - Harvard Gazette

Posted in Rhode Island Stem Cells | Comments Off on Paul Choi and Leslie Tolbert to lead Board of Overseers – Harvard Gazette

Multiple Diagnoses Are the Norm With Mental Illness and a New Genetic Study Explains Why – Neuroscience News

Posted: May 15, 2022 at 2:03 am

Summary: Study reports an overlap between genetic architecture and co-morbid mental health diagnosis. Researchers found 70% of the genetic signals associated with schizophrenia were also linked to bipolar disorder. Anorexia and OCD have a strong, shared genetic architecture.

Source: University of Colorado

More than half of people diagnosed with one psychiatric disorder will be diagnosed with a second or third in their lifetime. About a third have four or more.

This can make treatment challenging and leave patients feeling unlucky and discouraged.

But a sweeping new analysis of 11 majorpsychiatric disordersoffers new insight into why comorbidities are the norm, rather than the exception, when it comes to mental illness.

The study, published this week in the journalNature Genetics, found that while there is no gene or set of genes underlying risk for all of them, subsets of disordersincluding bipolar disorder and schizophrenia; anorexia nervosa and obsessive-compulsive disorder; andmajor depressionand anxietydo share a common genetic architecture.

Our findings confirm that high comorbidity across some disorders in part reflects overlapping pathways of genetic risk, said lead author Andrew Grotzinger, an assistant professor in the Department of Psychology and Neuroscience.

The finding could ultimately open the door to treatments that address multiple psychiatric disorders at once and help reshape the way diagnoses are given, he said.

If you had a cold, you wouldnt want to be diagnosed with coughing disorder, sneezing disorder and aching joints disorder, Grotzinger said.

This study is a stepping stone toward creating a diagnostic manual that better maps on to what is actually happening biologically.

How the study worked

For the study, Grotzinger and colleagues at University of Texas at Austin, Vrije Universiteit Amsterdam and other collaborating institutions analyzed publicly available genome-wide association (GWAS) data from hundreds of thousands of people who submittedgenetic materialto large-scale datasets, such as the UK Biobank and the Psychiatric Genomics Consortium.

They looked at genes associated with 11 disorders, including: schizophrenia, bipolar disorder,major depressive disorder, anxiety disorder, anorexia nervosa, obsessive-compulsive disorder, Tourette syndrome, post-traumatic stress disorder, problematic alcohol use, ADHD and autism.

In addition, they looked at data gathered via wearable movement tracking devices, and survey data documenting physical and behavioral traits.

Then they applied novel statistical genetic methods to identify common patterns across disorders.

Linked diagnoses

They found 70% of the genetic signal associated with schizophrenia is also associated with bipolar disorder. That finding was surprising as, under current diagnostic guidelines, clinicians typically will not diagnose an individual with both.

They also found anorexia nervosa andobsessive-compulsive disorderhave a strong, shared genetic architecture, and that people with a genetic predisposition to have a smaller body type or low BMI (body mass index), also tend to have agenetic predispositionto these disorders.

Not surprisingly, as the two diagnoses often go together, the study found a large genetic overlap between anxiety disorder and major depressive disorder.

When analyzing accelerometer data, the researchers found disorders that tend to cluster together also tend to share genes that influence how and when we move around during the day.

For instance, those with internalizing disorders, such as anxiety and depression, tend to have a genetic architecture associated with low movement throughout the day.

Compulsive disorders (OCD, anorexia) tend to correlate with genes associated with higher movement throughout the day, and psychotic disorders (schizophrenia and bipolar disorder) tend to genetically correlate with excess movement in the early morning hours.

When you think about it, it makes sense, said Grotzinger, noting that depressed individuals often present as fatigued or low energy, while those with compulsive disorders can have difficulty sitting still.

In all, the study identifies 152 genetic variants shared across multiple disorders, including those already known to influence certain types of brain cells.

For instance, gene variants that influence excitatory and GABAergic brain neuronswhich are involved in critical signaling pathways in the brainappear to strongly underlie the genetic signal that is shared across schizophrenia andbipolar disorder.

Whats next

While much more needs to be done to determine exactly what the identified genes do, Grotzinger sees the research as a first step toward developing therapies that can address multiple disorders with one treatment.

People are more likely today to be prescribed multiple medications intended to treat multiple diagnoses and in some instances those medicines can have side effects, he said.

By identifying what is shared across these issues, we can hopefully come up with ways to target them in a different way that doesnt require four separate pills or four separate psychotherapy interventions.

Meantime, just understanding the genetics underlying their disorders may provide comfort to some.

Its important for people to know they didnt just get a terrible roll of the dice in lifethat they are not facing multiple different issues but rather one set of risk factors bleeding into them all.

Author: Press OfficeSource: University of ColoradoContact: Press Office University of ColoradoImage: The image is in the public domain

Original Research: Open access.Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysis by Andrew D. Grotzinger et al. Nature Genetics

Abstract

Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysis

We interrogate the joint genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysis.

We identify four broad factors (neurodevelopmental, compulsive, psychotic and internalizing) that underlie genetic correlations among the disorders and test whether these factors adequately explain their genetic correlations with biobehavioral traits.

We introduce stratified genomic structural equation modeling, which we use to identify gene sets that disproportionately contribute to genetic risk sharing. This includes protein-truncating variant-intolerant genes expressed in excitatory and GABAergic brain cells that are enriched for genetic overlap across disorders with psychotic features.

Multivariate association analyses detect 152 (20 new) independent loci that act on the individual factors and identify nine loci that act heterogeneously across disorders within a factor.

Despite moderate-to-high genetic correlations across all 11 disorders, we find little utility of a single dimension of genetic risk across psychiatric disorders either at the level of biobehavioral correlates or at the level of individual variants.

See the original post here:
Multiple Diagnoses Are the Norm With Mental Illness and a New Genetic Study Explains Why - Neuroscience News

Posted in Molecular Genetics | Comments Off on Multiple Diagnoses Are the Norm With Mental Illness and a New Genetic Study Explains Why – Neuroscience News

Joubert Syndrome: the link between intellectual disability and defects in the hippocampus – EurekAlert

Posted: May 15, 2022 at 2:03 am

image:Children with Joubert Syndrome, like the girl in the image, may face a brighter future if hippocampal defects can be addressed. view more

Credit: JSUK

An important link has been found between the intellectual disability experienced by children with the rare disease Joubert Syndrome (JS) and defects in the hippocampus. The hippocampus is the part of the brain associated with learning and memory. It also plays a role in various neurological and psychiatric disorders.

Biologists at the University of Bath in the UK, led byDr Vasanta Subramanian,made this link in animal models by manipulating a gene (one of 34) known to cause JS in humans. Results fromthe studyare published inHuman Molecular Genetics.

By creating a deletion in the gene Talpid3 in healthy mice, graduate student Andrew L Bashford found that animals went on to develop defects to the primary cilia a cell structure that is essential in the development of the hippocampus. When examining the brains of mutant animals, the researchers observed defects in the hippocampus that bore a striking resemblance to those found in children with JS.

The primary cilia long, thin organelles that protrude from the surface of most cells work like cellular antennae, sending signals from the external environment of the cell to the interior, instructing the cell on how to behave (e.g. should it migrate, divide, stop dividing?). Primary cilia are important for the structure and function of many types of cells, including brain cells.

The findings from the study suggest a link between hippocampal defects, and the learning and memory deficits seen in JS patients. Malformations in the hindbrain (the lower part of the brainstem) are already known to be responsible for many of the physical symptoms associated with JS.

This is the first time we have seen a link between changes to the hippocampus and this disease in mouse models, said Dr Subramanian. This is an exciting area of research that we hope to continue making a contribution to. Joubert Syndrome is one of many rare diseases that has a devastating impact on those affected and is now rightly getting the research attention it deserves.

With further research on animal models, Dr Subramanian and her team expect to deepen their understanding of the causes of JS. In time, they hope drugs will be developed to target some of the genes or proteins involved in the disease, thereby alleviating symptoms or stopping the disease from developing in the first place.

Joubert Syndrome is a rare childhood disease that leads to poor muscle coordination, developmental delay, abnormal eye movements and neonatal breathing abnormalities. It is estimated that between 1 in 80,000 and 1 in 100,000 newborns are affected by the condition.

Speaking on behalf of the family-support organisation Joubert Syndrome UK, Faith Douthwaite said: We are delighted to hear about this new research, and also appreciate the dedication of medical professionals who continue to unravel the mysteries of Joubert Syndrome so as to improve the health and wellbeing of our beautiful and unique children.

Human Molecular Genetics

Experimental study

Animals

Hippocampal neurogenesis is impaired in mice with a deletion in the coiled coil domain of Talpid3-implications for Joubert Syndrome

26-Apr-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post:
Joubert Syndrome: the link between intellectual disability and defects in the hippocampus - EurekAlert

Posted in Molecular Genetics | Comments Off on Joubert Syndrome: the link between intellectual disability and defects in the hippocampus – EurekAlert

25 students and recent graduates awarded 2022 Fulbright grants | Penn Today – Penn Today

Posted: May 15, 2022 at 2:03 am

Twenty-five University of Pennsylvania students and alumni have been offered Fulbright grants for the 2022-23 academic year, including 18 seniors who will graduate May 16.

They will conduct research, pursue graduate degrees, or teach English in Colombia, France, Germany, Greece, India, Jordan, Mexico, Portugal, Spain, Sweden, Switzerland, Taiwan, Timor-Leste and the United Kingdom.

The Fulbright Program is the United States governments flagship international educational exchange program, awarding grants to fund as long as 12 months of international experience.

Most of the recipients applied for the Fulbright with support from Penns Center for Undergraduate Research and Fellowships.

Penn Fulbright grant recipients for 2022-23:

Aishwarya Balaji, from Frankfort, Kentucky, will graduate with the Class of 2022 with a bachelors degree in psychology and a minor in chemistry from the College of Arts and Sciences. She has been offered a Fulbright to conduct research on implicit biases on lemurs at the German Primate Center in Gttingen, Germany.

Gavin Blasdel, from Baltimore, is a Ph.D. candidate in ancient history in the School of Arts & Sciences. He has been offered a Fulbright to conduct research in Greece for his dissertation on the inscribed honorific statue monuments of Athens during the Roman Empire.

Lilian Chen, from San Jose, California, will graduate with the Class of 2022 with a degree in nursing and health care management through a dual-degree program between the School of Nursing and the Wharton School. She has been offered a Fulbright to teach English in Taiwan.

Ria Chinchankar, from Dubai, United Arab Emirates, will graduate in the Class of 2022 from Wharton, with a concentration in behavioral economics and business analytics. She has been offered a Fulbright to teach English in Mexico.

Amira Chowdhury, from Glendale, California, will graduate in the Class of 2022 with a bachelors degree in urban studies and political science and a minor in urban education, from the College. She is also graduating with her masters degree in social policy from the School of Social Policy & Practice. She has been offered a Fulbright to teach English in Timor-Leste.

Luke Coleman, from Dayton, Ohio, will graduate with the Class of 2022 with a bachelors degree from the College in philosophy, politics, and economics with a concentration in public policy and governance and minors in Hispanic studies and survey research and data analytics. He has been offered a Fulbright to teach English in Spain.

Sonali Deliwala, from Yardley, Pennsylvania, will graduate with the Class of 2022 with a bachelors degree in political science and economics and a minor in creative writing from the College. She has been offered a Fulbright to conduct research in India.

Alice Heyeh, from Chappaqua, New York, will graduate with the Class of 2022 with a bachelors degree in communication with a concentration in culture and society and minors in design and consumer psychology from the College. She has been offered a U.S.-U.K. Fulbright Arts Award to pursue a masters degree in communication design at Northumbria University in the United Kingdom.

Robin Hu, from Los Angeles, will graduate with the Class of 2022 with a bachelors degree in communication with a concentration in data and network science and a minor in chemistry from the College. She has been offered a Fulbright to teach English in Taiwan.

JAun Johnson, from Bowie, Maryland, will graduate with the Class of 2022 with a bachelors degree in dual romance languages with a concentration in French and Hispanic studies and a minor in chemistry from the College. He has been offered a Fulbright to teach English in Colombia.

Jordyn Kaplan, from Media, Pennsylvania, will graduate with the Class of 2022 with a bachelor's degree in American history and minors in urban education and political science from the College. She has been offered a Fulbright to teach English in Spain.

Erin Kraskewicz, from Elizabethtown, Pennsylvania, will graduate with the Class of 2022 with a bachelors degree in international relations and history from the College. She has been offered a Fulbright to teach English in Spain.

Becca Lee, from Pittsburgh, graduated with a bachelors degree in biochemistry and a minor in sociology in 2020 from the College and with a masters degree in chemistry in 2021 from the School of Arts & Sciences. She has been offered a Fulbright to teach English in Taiwan.

Shaila Lothe, from Richmond, Virginia, will graduate with the Class of 2022 with a dual degree majoring in political science in the College and concentrating in behavioral economics in Wharton and minoring in Hispanic studies. She has been offered a Fulbright in which she will be paired with a company or non-governmental organization and study international business in Mexico.

Brendan Lui, from Potomac, Maryland, will graduate with the Class of 2022 with a bachelors degree in political science with a concentration in comparative politics from the College. He has been offered a Fulbright to pursue a masters degree in political science at the University of Cologne in Germany.

Amin Marei, from Philadelphia, is a Ph.D. candidate in education, culture, and society in the Graduate School of Education. She has been offered a Fulbright to conduct research in Jordan.

Rebecca Morse, from Acton, Massachusetts, will graduate with the Class of 2022 with a bachelors degree in biology with a concentration in mechanisms of disease and minors in chemistry and French from the College. She has been offered a Fulbright to conduct research at the University of Geneva in Switzerland, studying the effect of previous acute infections on COVID-19 vaccine responses.

Wil Prall, from Philadelphia, is a Ph.D. candidate in biology concentrating in cell and molecular genetics in the School of Arts & Sciences. He has been offered a Fulbright to continue his thesis work in France at the Universite Paris-Saclay.

Avneet Randhawa, from Houston, Texas, graduated in 2021 with a bachelors degree in English with a concentration in 20th and 21st century modernisms from the College. She has been offered a Fulbright to teach English in Spain.

Kaitlyn Rentala, from Rye, New York, will graduate with the Class of 2022 with a bachelors degree in philosophy, politics, and economics with a concentration in globalization from the College. She is a recipient of a Fulbright-Schuman research grant to the European Union and will spend the academic year in Germany and the Netherlands conducting research on E.U. tech policy and political philosophy.

Anyara Rodriguez, from Santo Domingo, Dominican Republic, will graduate with the Class of 2022 with a bachelors degree in neuroscience and political science with a minor in chemistry from the College. She has been offered a Fulbright to study the sleep and circadian influences on memory retrieval at Ludwig Maximillian University of Munich in Germany.

Lily Snider, from Philadelphia, graduated in 2020 with a bachelors degree in English with a concentration in creative writing from the College. She has been offered a Fulbright grant to complete a nonfiction, research-based creative writing project in the Azores, Portugal.

Stefan Tomov, from Las Vegas, Nevada, will graduate with the Class of 2022 with a bachelors degree in international studies and a Chinese language certificate from the College and a concentration in business analytics from Wharton as part of the Huntsman Program in International Studies and Business. He has been offered a Fulbright to teach English in Taiwan.

Irene Yee, from Manlius, New York, will graduate with the Class of 2022 with a bachelors degree in neuroscience and minors in chemistry and gender studies from the College. She has been offered a Fulbright to conduct research in Sweden.

Chloe Zhou, from San Jose, California, will graduate with the Class of 2022 with a masters degree in education from the Graduate School of Education. Zhou was part of the Urban Teaching Apprenticeship Program to be certified to teach English in secondary classrooms. Zhou has been offered a Fulbright to teach English in Taiwan.

Follow this link:
25 students and recent graduates awarded 2022 Fulbright grants | Penn Today - Penn Today

Posted in Molecular Genetics | Comments Off on 25 students and recent graduates awarded 2022 Fulbright grants | Penn Today – Penn Today

Page 456«..1020..455456457458..470480..»